Currency In USD
| Previous Close | 52.97 |
| Open | 52.97 |
| Day High | 52.97 |
| Day Low | 52.95 |
| 52-Week High | 53.19 |
| 52-Week Low | 2.66 |
| Volume | 6.33M |
| Average Volume | 5.92M |
| Market Cap | 4.77B |
| PE | -51.41 |
| EPS | -1.03 |
| Moving Average 50 Days | 50.15 |
| Moving Average 200 Days | 29.48 |
| Change | -0.02 |
Data not available
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 9:05 PM GMT
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the followin
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 11, 2025 9:05 PM GMT
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of